D9Z Stock Overview
A medical company, operates a network of ophthalmology clinics. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Clínica Baviera, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €34.60 |
| 52 Week High | €39.50 |
| 52 Week Low | €20.90 |
| Beta | 0.68 |
| 11 Month Change | -8.95% |
| 3 Month Change | 17.69% |
| 1 Year Change | 65.55% |
| 33 Year Change | 80.21% |
| 5 Year Change | 167.18% |
| Change since IPO | 50.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| D9Z | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -2.0% | 1.1% | 0.2% |
| 1Y | 65.6% | 16.5% | 8.5% |
Return vs Industry: D9Z exceeded the German Healthcare industry which returned 16.5% over the past year.
Return vs Market: D9Z exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| D9Z volatility | |
|---|---|
| D9Z Average Weekly Movement | 6.3% |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: D9Z has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: D9Z's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1,326 | Eduardo Baviera Sabater | www.clinicabaviera.com |
Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, cornea, neuroftalmología, and vías lagrimales treatments.
Clínica Baviera, S.A. Fundamentals Summary
| D9Z fundamental statistics | |
|---|---|
| Market cap | €567.32m |
| Earnings (TTM) | €38.41m |
| Revenue (TTM) | €243.31m |
14.8x
P/E Ratio2.3x
P/S RatioIs D9Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D9Z income statement (TTM) | |
|---|---|
| Revenue | €243.31m |
| Cost of Revenue | €122.92m |
| Gross Profit | €120.39m |
| Other Expenses | €81.98m |
| Earnings | €38.41m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.36 |
| Gross Margin | 49.48% |
| Net Profit Margin | 15.79% |
| Debt/Equity Ratio | 1.9% |
How did D9Z perform over the long term?
See historical performance and comparison